MD Anderson and Takeda Announce Collaboration to Accelerate Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
November 05, 2019
November 05, 2019
HOUSTON, Texas, Nov. 5 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.
Under the ag . . .
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.
Under the ag . . .